Form 4: Recursion Pharmaceuticals CFO Michael Secora Executes Stock Option and Sells Shares Under 10b5-1 Plan

Michael Secora, CFO of Recursion Pharmaceuticals, exercised stock options and sold shares of Class A Common Stock under a pre-arranged 10b5-1 trading plan.

Summary

• Michael Secora, the Chief Financial Officer of Recursion Pharmaceuticals, executed transactions involving the company's Class A Common Stock.
• On June 13 and 14, 2024, Secora exercised stock options to acquire 39,375 shares on each day at an exercise price of $2.22 per share.
• Concurrently, Secora sold 15,000 shares on each day at weighted average prices of $9.3199 and $9.2721, respectively.
• These transactions were conducted under a pre-arranged 10b5-1 trading plan adopted on March 1, 2024.
• Following these transactions, Secora directly owns 1,267,843 shares of Class A Common Stock and holds options to purchase a significant number of additional shares at various exercise prices and expiration dates.

Sentiment

Score: 5

Explanation: Neutral sentiment as the document simply reports insider trading activity under a pre-existing plan. There is no indication of positive or negative implications for the company.

Industry Context

This filing is a routine disclosure of insider transactions. It is common for executives to utilize 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information.

Comparison to Industry Standards

• Insider trading activity is closely monitored across the pharmaceutical industry.
• Companies like Amgen, Pfizer, and Johnson & Johnson also have executives who regularly file Form 4s related to stock option exercises and sales.
• The use of 10b5-1 plans is a standard practice to ensure compliance with insider trading regulations.

Key Dates